Navigation Links
Particle Sciences Develops Zero-Order-Release Combination Device Technology
Date:8/26/2008

BETHLEHEM, Pa., Aug. 26 /PRNewswire/ -- Particle Sciences Inc. today announced the development of their "Microreservoir" technology enabling the manufacture of drug-eluting polymer medical devices that release drugs at constant rates over 30 days or more. This technology has already been used by Particles Sciences to develop drug eluting vaginal rings. "Drug release from polymeric materials often follows a burst/first-order kinetic profile which may not be clinically desired," explained Andrew Loxley, Director of New Technologies. "Traditionally the burst effect has been reduced by confining the API to a reservoir within the device, but this adds complexity and cost to production," he added. In their approach, Particle Sciences' scientists first encapsulate the drug in polymer microparticles before blending with the polymer used to make the final product. Robert Lee, VP of Pharmaceutical Development commented, "Microencapsulating the drug enabled the use of simple molding processes to fabricate devices containing tens of thousands of 'microreservoirs,' and the devices exhibit constant drug release profiles equivalent to traditional reservoir devices. This approach greatly simplifies production and adds tremendous flexibility to both single and multi-drug devices." Particle Sciences sees broad utility for this proprietary technology, which is applicable to polymer devices, films, coatings and other polymeric structures from which drugs or other materials are to be released at a constant rate. For more information on Particles Sciences, visit http://www.particlesciences.com.

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Pa
'/>"/>

SOURCE Particle Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. New disease-fighting nanoparticles look like miniature pastries
2. Nanoparticles + light = dead tumor cells
3. Using magenetic nanoparticles to combat cancer
4. Nanoparticle Stops Cancer From Spreading
5. Waves, particles and medicine in Houston
6. Smart bomb nanoparticle strategy impacts metastasis
7. MAP Pharmaceuticals Acquires Proprietary Drug Particle Formulation Technology From Eiffel/Telesso Technologies Limited
8. Nanoparticles aid bone growth
9. Magnetic nanoparticles: Suitable for cancer therapy?
10. Brown chemists create cancer-detecting nanoparticles
11. Scientists image a single HIV particle being born

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., A team of Kendall Hunt ...er of the Year Award at the recent National Associ...e in St. Louis, November 5-7, 2009. , ...-- A team of Kendall Hunt authors earned the 2009 ...the recent National Association for Gifted Childre...
(Date:12/2/2009)..., , Ad in Today,s Washington Post ...ewswire-USNewswire/ -- If the Catholic bishops ...tative measures we take for granted may be under t...ght to bear on the debate over healthcare reform h...Washington Post warns of the likely impact if tha...
(Date:12/2/2009)... Insect repellents suspected in birth defect that ..., WEDNESDAY, Dec. 2 (HealthDay News) -- Male babie...rst three months of pregnancy appear to be at incr...researchers report. , This birth defect, which ...ves premature shortening of the urethra, the tube ...
(Date:12/2/2009)..., , Fruit flies may seem like unlikely heroes in ...ggests that these insects already used to study d...entists are reporting that fruit flies can be used... studying the effects of cocaine and other drugs o...n ACS Chemical Neuroscience , a new monthly journ...
(Date:12/2/2009)..., MyCareTeam, Inc., a lea...gement software, has released the newest version o...udes hypertension, congestive heart failure and we...isting diabetes monitoring features. , ...9 -- MyCareTeam, Inc., a leading vendor of Interne...
Breaking Medicine News(10 mins):Health News:Kendall Hunt Authors Earn NAGC “Paper of the Year” Award 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2Health News:MyCareTeam™ Significantly Extends Diabetes Offering to Include Management of Hypertension, Obesity, and Congestive Heart Failure 2
...our out of five hospitalized children receive medi...r adults//. The authors fear that treating childre...omes. "We measured the magnitude of off-labe...hiladelphia. "Given the nature of the available da...
...in Nigeria has been a success, but continued commi...icate the virus from northern states, say official...ive was launched in May 2006 by the National Progr...egions still affected by the virus. People i...
...ly diagnosis of lung cancer. They hope the analysi.../ lining the airways leading to the lungs can be u...s more effective. Lung cancer is the most dead...d and nearly 29,000 deaths. Part of the reas...
...sults of a study showing clearly that soft drinks ...gher body weight, a decrease in calcium and other ... The report also noted that studies funded b...le analyzed 88 previously published studies obtain...
...e accurate amount of fat in a human body, accordin... as the standard for measuring the amount of fat i...'s body weight divided by the square of their heig... at a greater risk of heart disease, diabetes and ...
...on educated in India, was Monday conferred with th... Ruit has conducted over 70,000 surgeries fo...indness in the subcontinent. "It is an apt a...d surgeon at the award ceremony here. Ruit h...
Other Medicine News:Health News:Prescribing Off Label Drugs for Children may Be Hazardous 2Health News:Prescribing Off Label Drugs for Children may Be Hazardous 3Health News:Nigerian Programme Increases Polio Immunisation 2Health News:Gene Cell Test may Aid Early Lung Cancer Diagnosis 2Health News:Yale Researchers Weigh the Science on Soft Drinks and Health 2
(Date:12/2/2009)...c. 2 Novartis announced today that...on Tasigna® (nilotinib) 200 mg capsules in a ...strength of the company,s hematology portfolio in ...a, at the 51st American Society of Hematology (ASH...pany,s current therapies and investigational agent...
(Date:12/1/2009)...wire/ -- Reportlinker.com announces that a new mar... ,, Medical Oxygen Systems - Global Market Op...0164334/Medical-Oxygen-Systems---Global-Market-Opp...stems market for home healthcare setting is reckon...wth expectations stem from demographic factors suc...
(Date:12/1/2009)...wire/ -- Reportlinker.com announces that a new mar... ,, Molecular Diagnostics - A World Market Rev...olecular-Diagnostics---A-World-Market-Review.html ...n by several growth factors that include the need ... combine optimized sample preparation, analysis, a...
Breaking Medicine Technology:Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 2Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 3Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 4Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 5Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 6Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities 7Reportlinker Adds Molecular Diagnostics - A World Market Review 2Reportlinker Adds Molecular Diagnostics - A World Market Review 3Reportlinker Adds Molecular Diagnostics - A World Market Review 4Reportlinker Adds Molecular Diagnostics - A World Market Review 5Reportlinker Adds Molecular Diagnostics - A World Market Review 6OneDotOneLife org Saving the Lives of More Than 2 Million Children 5048 1OneDotOneLife org Saving the Lives of More Than 2 Million Children 5048 2Pres Clinton Announces Commitment From Inter American Development Bank Global Network for Neglected Tropical Diseases and Pan American Health Organ 5046 1Pres Clinton Announces Commitment From Inter American Development Bank Global Network for Neglected Tropical Diseases and Pan American Health Organ 5046 2Pres Clinton Announces Commitment From Inter American Development Bank Global Network for Neglected Tropical Diseases and Pan American Health Organ 5046 3Regence to Cover Administration Costs of H1N1 Vaccine for Fully Insured Groups Individuals This Flu Season 5044 1Regence to Cover Administration Costs of H1N1 Vaccine for Fully Insured Groups Individuals This Flu Season 5044 2Regence to Cover Administration Costs of H1N1 Vaccine for Fully Insured Groups Individuals This Flu Season 5044 3
...J., Oct. 29 Sanofi-aventis,announced today that t...d,Apidra(R) (insulin glulisine [rDNA origin] injec...ears and older) with diabetes mellitus., The appr...FDA review of,a 26-week, phase III, open-label, ac... insulin lispro, in 572 children and adolescents (...
..., Oct. 29 CuraGen Corporation,(Nasdaq: CRGN ), a...on,oncology, announced today that Company executiv...t 11:00 a.m. ET on Monday, November 3, 2008,follow...sults and to review,preliminary data from CuraGen,...for the treatment of advanced melanoma., Data fro...
Other Medicine Technology:FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 2FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 3FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 4FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes 5CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on November 3, 2008 2
...rade; is a pressure relief mattress overlay design...ow air loss therapy for those patient with skin br...ONS: , Patients whose body weight and size pose a...patient or staff during the performance of routine...
...providing a flexible environment for patient care,... comfort, support, treatment and prevention., ,IN... ,Large patients at risk for pressure ulcers ,Any ...enefit from a pressure reduction surface ,Patients...
Triflex™ II Bariatric Bed
...sty Max 10 Nebulizer W/ 7` CR Resistant Oxygen Tub...times , ,Provide fine particles with a tighter di...les) than conventional nebulizers, ,Our AirLife&t...ers deliver fast and effective treatment more effi...
Medicine Products: